Company Analysis

Erasca, Inc. (ERAS)

Nasdaq: ERAS · Pharmaceutical Preparations · San Diego, CA · filing with the SEC since 2019
Grade5.2
◀ Past 5.4● Present 5.8▶ Future 4.6
6 est.

Who runs Erasca, Inc.

Officers and directors as they report to the SEC on Forms 3, 4 and 5, named as filed
Chief executive, as filed
Lim Jonathan E
Chairman & CEO. First filing Jul 2021, latest Jan 30, 2026, 6 filings in all.
Officers reporting now
5
of 12 people with a filing in the last fifteen months
Directors reporting now
7
17 people on the record since 2021
Officerssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameTitle as filedFirst filingLatest filingSales, 12 months
Fuchs Charles S.President, R&DAug 2026Aug 12, 2026none
Garner EbunChief Legal OfficerJul 2021Apr 3, 20262 · $2.0M
Morris ShannonChief Medical OfficerApr 2023Mar 6, 20261 · $300,000
Lim Jonathan EChairman & CEOJul 2021Jan 30, 2026none
Chacko David M.CFO and CBOJul 2021Jan 30, 2026none
Directorssales are open-market, Sep 30, 2025 to Sep 30, 2026
NameRoleFirst filingLatest filingSales, 12 months
Bristol James ArthurdirectorJul 2021Jun 29, 2026none
Casdin Alexander W.directorJul 2021Jun 29, 2026none
Hambleton JuliedirectorJul 2021Jun 29, 2026none
Liu Jean IdirectorApr 2022Jun 29, 2026none
Multani Pratik SdirectorJul 2021Jun 29, 2026none
Start Valerie Denise HardingdirectorJul 2021Jun 29, 2026none
Varney Michael DaviddirectorJul 2021Jan 30, 2026none
Earlier names on the record16, newest filing first

A person is listed as reporting now after a filing in the last fifteen months. The record shows when someone last filed; it does not say why they stopped. Each name links to the filings on sec.gov.

SI Assistanton ERAS · research, not advice